Blogs

Melanoma CPG Update v3.1 Now Available

By SITC Scientific Publications News posted 5 days ago
1 person likes this.
In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “ SITC Living Guidelines ” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and incorporate the leading expert guidance in cancer immunotherapy care – a vital service to treating clinicians and those along the whole cancer care continuum. Rapid Update v3.1 Summary The information below provides an overview ...
0 comments

Gynecologic Cancer CPG Update v1.1 Now Available

By SITC Scientific Publications News posted 12 days ago
1 person likes this.
In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “ SITC Living Guidelines ” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and incorporate the leading expert guidance in cancer immunotherapy care – a vital service to treating clinicians and those along the whole cancer care continuum. Rapid Update v1.1 Summary The information below provides ...
0 comments

Breast CPG Update v1.2 Now Available

By SITC Scientific Publications News posted 29 days ago
1 person likes this.
In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “ SITC Living Guidelines ” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and incorporate the leading expert guidance in cancer immunotherapy care – a vital service to treating clinicians and those along the whole cancer care continuum. Rapid Upd ate v1.2 Summary The information below ...
0 comments

SITC Living Guidelines – Rapid Updates to Published Clinical Practice Guidelines

By SITC Scientific Publications News posted 05-23-2024
1 person likes this.
In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “SITC Living Guideline” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and incorporate the leading expert guidance in cancer immunotherapy care – a vital service to treating clinicians and those along the whole cancer care continuum. All active SITC guidelines are reviewed at least annually for needed ...
0 comments

Nonmelanoma Skin Cancer CPG Update v1.1 Now Available

By SITC Scientific Publications News posted 03-19-2024
1 person likes this.
In accordance with the Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines (CPGs), SITC CPGs undergo periodic evaluation to assess if new evidence necessitates modifications to recommendations, treatment algorithms, or other guideline content. This is done through our “ SITC Living Guidelines ” rapid update protocols designed to ensure SITC’s CPGs are up-to-date with cutting-edge thinking and incorporate the leading expert guidance in cancer immunotherapy care – a vital service to treating clinicians and those along the whole cancer care continuum. Rapid Update v1.1 Summary The information below provides an ...
0 comments

New SITC Melanoma CPG Published in JITC

By SITC Scientific Publications News posted 10-18-2023
1 person likes this.
On behalf of the Society for Immunotherapy of Cancer (SITC) and the SITC Melanoma Guideline Expert Panel, we are pleased to announce the publication of SITC’s Melanoma Clinical Practice Guideline (CPG), version 3.0. This manuscript is SITC’s first CPG covering immunotherapy indications for cutaneous melanoma as well as rarer subtypes of the disease. Immunotherapy is a standard of care option for both BRAF -wildtype and BRAFV600 -mutated melanoma. Exciting new data are carving out indications for adjuvant immune checkpoint inhibitor (ICI) therapy for resected stage IIB and IIC disease, neoadjuvant followed by adjuvant ICI therapy for resectable stage ...
0 comments

New SITC Gynecologic Cancer CPG Published in JITC

By SITC Scientific Publications News posted 06-09-2023
1 person likes this.
On behalf of the Society for Immunotherapy of Cancer (SITC) and the SITC Gynecologic Cancer Immunotherapy Guideline Expert Panel, we are pleased to announce the publication of SITC’s Gynecologic Cancer Clinical Practice Guideline (CPG). This manuscript is SITC’s first CPG covering immunotherapy indications for cervical, endometrial, and ovarian cancer, as well as other rare gynecologic cancers. The treatment landscape in gynecologic cancers is dynamic. In recent years, immune checkpoint inhibitors (ICIs) have become the standard of care for advanced disease in both cervical and endometrial cancer. Moreover, recent phase III trials in endometrial cancer ...
0 comments

New SITC Gastrointestinal Cancer CPG Published in JITC

By SITC Scientific Publications News posted 06-07-2023
Be the first person to like this.
SITC is pleased to announce the publication of our newest guideline, " Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer. " Clinicians will find this guideline an invaluable resource to assist in navigating the challenging issues that sometimes arise during the treatment of gastrointestinal cancer, including treatment selection based on histology and biomarker status, toxicity management, and quality of life and patient education. This guideline covers immunotherapy for the treatment of esophageal, GE junction, gastric, duodenal and distal small bowel, pancreaticobiliary, colorectal, ...
0 comments

Open Comment Period for SITC’s Melanoma Guideline Closes March 16

By SITC Scientific Publications News posted 02-23-2023
1 person likes this.
The Society for Immunotherapy of Cancer (SITC) Melanoma Immunotherapy Guideline Expert Panel is pleased to invite public comment on the draft clinical practice guideline (CPG) “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma,” an update to the society’s 2018 CPG for this disease setting. During SITC’s open comment period, key stakeholders and other experts in the field may critically review a confidential copy of the CPG draft and provide input prior to its publication. More information on how to gain access to the draft manuscript can be found on the open comment page of the SITC website. ...
0 comments

Open Comment Periods for SITC’s Gynecologic Cancer and Gastrointestinal Cancer Guidelines Close January 27

By SITC Scientific Publications News posted 01-12-2023
Be the first person to like this.
The Society for Immunotherapy of Cancer (SITC) is pleased to invite public comment on two new draft clinical practice guidelines (CPGs): “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer” “Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gynecologic cancer” During SITC’s open comment period, key stakeholders and other experts in the field may critically review a confidential copy of the CPG draft and provide input prior to its publication. More information on how to gain access to the draft manuscript can be ...
0 comments

Help SITC Performance Test Our Next Quality Measure – Apply by January 5

By SITC Scientific Publications News posted 12-20-2022
1 person likes this.
The Society for Immunotherapy of Cancer (SITC) is currently recruiting practices for clinician-level testing of the draft quality measure: Positive PD-L1 Biomarker Expression Test Result Prior to First-Line Immune Checkpoint Inhibitor Therapy. If interested, please take the time to fill out this short interest form by 01/05/2023. Participating practices will answer approximately 30 questions via Survey Monkey on a random sample of at least 25 patients with metastatic non-small cell lung cancer and/or squamous cell carcinoma of the head and neck who received first-line immune checkpoint inhibitors without chemotherapy. No Protected Health Information ...
0 comments

New Interactive Tools for SITC’s Nonmelanoma Skin Cancer and Lung Cancer & Mesothelioma Guidelines

By SITC Scientific Publications News posted 11-15-2022
1 person likes this.
New interactive tools have been developed and integrated into the SITC CPG Mobile App for two of SITC’s guidelines that published in 2022. An overview of the guideline content as well as a highlight of the new tools and resources are outlined below. SITC’s Nonmelanoma Skin Cancer Immunotherapy Clinical Practice Guideline SITC’s nonmelanoma skin cancer CPG is the definitive source for expert panel recommendations on the use of immunotherapy for the treatment of Merkel cell carcinoma (MCC), cutaneous squamous cell carcinoma (CSCC), basal cell carcinoma (BCC), and other rare subtypes, as well as biomarker testing, treatment selection, treatment of underrepresented ...
0 comments

New Guideline Information and Tools Available – Lymphoma, RCC, ICI-rAEs, Urothelial Cancer & Prostate Cancer

By SITC Scientific Publications News posted 11-09-2022
1 person likes this.
Previously published guidelines have new and updated content available only in the app. Below is an overview of the guidelines for which updates are available. A full description of the event that prompted the update as well as the overview of the new or updated content can be found on the “Guideline Updates” tiles for each guideline. Immune Checkpoint Inhibitor-related Adverse Events CPG – Updated recommendation on risk monitoring for major cardiac adverse events with anti-PD-1/TKI combinations Lymphoma CPG – Updated recommendations based on CAR T approvals for second-line treatment of large B cell lymphomas and third-line treatment of follicular lymphoma ...
0 comments

New SITC Nonmelanoma Skin Cancer CPG Published in JITC

By SITC Scientific Publications News posted 07-28-2022
1 person likes this.
SITC is pleased to announce the publication of our newest guideline, "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of nonmelanoma skin cancer." Clinicians will find this guideline an invaluable resource to assist in navigating the challenging issues that sometimes arise during the treatment of advanced nonmelanoma skin cancer, including treatment selection, immunosuppressed patient populations, toxicity management, assessment of atypical responses, and quality of life and survivorship concerns. This guideline covers immunotherapy for the treatment of Merkel cell carcinoma, cutaneous squamous cell ...
0 comments

New SITC Lung Cancer and Mesothelioma CPG Published in JITC

By SITC Scientific Publications News posted 05-31-2022
1 person likes this.
SITC is pleased to announce the publication of our newest guideline, " Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma . " This guideline will provide a valuable clinical decision-making tool to help guide oncologists and other advanced practice providers on key aspects of immunotherapy treatment of non-small cell lung cancer, small cell lung cancer, and mesothelioma. Guideline readers will not only find evidence- and expert consensus-based recommendations on immunotherapy for stage IV non-small cell lung cancer but also covering the recent new approvals for checkpoint ...
0 comments

SITC Cancer Immunotherapy Guidelines Mini Modules

By SITC Scientific Publications News posted 03-16-2022
1 person likes this.
SITC is pleased to announce a new educational offering for the society’s clinical practice guidelines – SITC’s Cancer Immunotherapy Guidelines Mini Modules. Designed for practitioners with a desire to learn but with limited time, the Mini Modules offer important key takeaways from the evidence- and consensus-based recommendations from the SITC clinical practice guidelines. Each Mini Module is a bite-sized video roughly 10 minutes in length focused on a single topic. Featuring members of the Expert Panel who developed the clinical practice guideline, the Mini Modules and are available here for the following disease and topic areas: SITC Acute Leukemia ...
0 comments

SITC Cancer Immunotherapy Guidelines Webinars

By SITC Scientific Publications News posted 03-11-2022
1 person likes this.
SITC’s Cancer Immunotherapy Guidelines Webinars connect clinicians with leading experts in the field and provide education about the evidence- and consensus-based recommendations in the clinical practice guidelines. On-demand content is now available for those who were not able to make it to the live webinars. Each webinar series offers an overview of the guideline, practical management pearls, and case studies program presented by the expert panel members and chairs who developed the guideline. For access to all on-demand webinars, please visit the Cancer Immunotherapy Guidelines Webinars website . Recently released series include: Clinical ...
0 comments

SITC CPG Mobile App Update – Multiple Myeloma Guideline: D-Kd PLEIADES data and FDA approval

By SITC Scientific Publications News posted 02-01-2022
1 person likes this.
The SITC Multiple Myeloma Expert Panel has updated the guidelines content and recommendations based on the November 30, 2021 FDA approval of daratumumab in combination with carfilzomib and dexamethasone (D-Kd) for adult patients with relapsed or refractory multiple myeloma who have received 1−3 prior lines of therapy. The approval was based on an overall response rate (ORR) of 84.8% (95% CI, 73.9% to 92.5%) with the majority of responses ongoing at 9 months in the PLEIADES trial (NCT03412565). The updates to this guideline are found in the Monoclonal Antibodies Expert Panel Recommendations section and Multiple Myeloma Key Monoclonal Antibody Therapies Trials ...
0 comments

SITC CPG Mobile App Update – Hepatocellular Carcinoma Guideline: New Treatment Algorithm

By SITC Scientific Publications News posted 01-01-2022
1 person likes this.
The new hepatocellular carcinoma immunotherapy treatment algorithm was derived from the expert panel recommendations in the published SITC clinical practice guideline . This algorithm, available only in the free SITC CPG mobile app , was developed to provide users with a convenient and intuitive tool to support clinical decision-making. January 1, 2022
0 comments

SITC CPG Update – Breast Cancer Guideline: Withdrawn indication for atezolizumab

By SITC Scientific Publications News posted 12-03-2021
1 person likes this.
On August 27, 2021, the indication for atezolizumab in combination with nab-paclitaxel as treatment for patients with triple-negative breast cancer (TNBC) whose tumors express PD-L1 was voluntarily withdrawn by the manufacturer. According to the press release announcing the withdrawal, the decision was not related to any changes in either the efficacy or safety associated with atezolizumab but rather to recent changes in the treatment landscape for TNBC. In light of the withdrawal, “ Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer ” has been updated in the journal publication as ...
0 comments